[Gene therapy and immunotherapy in prostatic carcinoma]

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Local prostate cancer (PC) is often curable with surgery, but treatments for metastatic and androgen-independent PC are limited.
• Molecular biology advancements are driving novel therapeutic strategies for advanced PC stages.
• Current therapies for advanced PC often yield unsatisfactory outcomes.

Purpose of the Study:

• To review novel gene and immunotherapy approaches for advanced prostate cancer.
• To highlight the potential of passive and active immunotherapies, including antibody and dendritic cell-based treatments.
• To discuss gene therapy strategies such as antisense and suicide gene therapy for PC.

Main Methods:

• Review of current research in gene and immunotherapy for prostate cancer.
• Analysis of early clinical trial data (Phase I/II) for chimeric/recombinant antibodies.
• Examination of dendritic cell-based active immunotherapy and gene therapy approaches (antisense, suicide gene therapy).

Main Results:

• Passive immunotherapy using antibodies shows promise in early clinical trials.
• Active immunotherapy with tumor antigen-loaded dendritic cells is a potential option.
• Antisense gene therapy may offer systemic treatment with limited toxic side effects.
• Theranostics are crucial for patient selection in antibody-based therapies.

Conclusions:

• Gene and immunotherapy represent promising novel treatment options for advanced prostate cancer.
• Personalized medicine and patient-specific treatments are key for future PC therapies.
• Further development of gene therapy vectors and identification of therapeutic targets are essential.